ROIVANT SCIENCES LTD. Deconsolidation, Gain (Loss), Amount
ROIVANT SCIENCES LTD. (ROIV) reported Deconsolidation, Gain (Loss), Amount of $11.03 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Income Statement › Other Income
us-gaap:DeconsolidationGainOrLossAmount · last filed 2026-05-20
- ROIVANT SCIENCES LTD. deconsolidation, gain (loss), amount for the quarter ending 2025-03-31 was $3.11M, a 79.84% decline year-over-year.
- ROIVANT SCIENCES LTD. deconsolidation, gain (loss), amount for the quarter ending 2024-12-31 was $0.00.
- ROIVANT SCIENCES LTD. deconsolidation, gain (loss), amount for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ROIVANT SCIENCES LTD. deconsolidation, gain (loss), amount for the quarter ending 2024-03-31 was $15.42M.
- ROIVANT SCIENCES LTD. deconsolidation, gain (loss), amount for fiscal 2026 was $11.03M, a 254.79% increase from fiscal 2025.
- ROIVANT SCIENCES LTD. deconsolidation, gain (loss), amount for fiscal 2025 was $3.11M, a 90.52% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. deconsolidation, gain (loss), amount for fiscal 2024 was $32.77M, a 11.94% increase from fiscal 2023.
- ROIVANT SCIENCES LTD. deconsolidation, gain (loss), amount for fiscal 2023 was $29.28M, a 480.76% increase from fiscal 2022.
| Period end | Deconsolidation, Gain (Loss), Amount 3 month | Deconsolidation, Gain (Loss), Amount 6 month | Deconsolidation, Gain (Loss), Amount 9 month | Deconsolidation, Gain (Loss), Amount 12 month |
|---|---|---|---|---|
| 2026-03-31 | $11.03M 10-K · filed 2026-05-20 | |||
| 2025-03-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $3.11M derived: sum of 2 quarters · filed 2026-05-20 | $3.11M derived: sum of 3 quarters · filed 2026-05-20 | $3.11M 10-K · filed 2026-05-20 |
| 2024-12-31 | $0.00 10-Q · filed 2025-02-10 | $0.00 derived: sum of 2 quarters · filed 2025-02-10 | $0.00 10-Q · filed 2025-02-10 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2024-03-31 | $15.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $15.42M derived: sum of 2 quarters · filed 2026-05-20 | $32.77M derived: sum of 3 quarters · filed 2026-05-20 | $32.77M 10-K · filed 2026-05-20 |
| 2023-12-31 | $0.00 10-Q · filed 2025-02-10 | $17.35M derived: sum of 2 quarters · filed 2025-02-10 | $17.35M 10-Q · filed 2025-02-10 | |
| 2023-09-30 | $17.35M 10-Q · filed 2024-11-12 | $17.35M 10-Q · filed 2024-11-12 | ||
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $12.51M derived: sum of 2 quarters · filed 2025-05-29 | $29.28M derived: sum of 3 quarters · filed 2025-05-29 | $29.28M 10-K · filed 2025-05-29 |
| 2022-12-31 | $12.51M 10-Q · filed 2024-02-13 | $29.28M derived: sum of 2 quarters · filed 2024-02-13 | $29.28M 10-Q · filed 2024-02-13 | |
| 2022-09-30 | $16.76M 10-Q · filed 2023-11-13 | $16.76M 10-Q · filed 2023-11-13 | ||
| 2022-03-31 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $5.04M derived: sum of 2 quarters · filed 2023-06-28 | $5.04M derived: sum of 3 quarters · filed 2023-06-28 | $5.04M 10-K · filed 2023-06-28 |
| 2021-12-31 | $0.00 10-Q · filed 2023-02-13 | $0.00 derived: sum of 2 quarters · filed 2023-02-13 | $0.00 10-Q · filed 2023-02-13 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |